Mometasone furoate/formoterol in the treatment of persistent asthma

References

• Pleis JR, Ward BW, Lucas JW. Summary health statistics for U.S. adults: National Health Interview Survey, 2009. National Center for Health Statistics. Vital Health Stat.10(249), 1–217 (2010).
   Google Scholar
• Bloom B, Cohen RA, Freeman G. Summary health statistics for US children: National Health Interview Survey, 2008. Vital Health Stat.10(244), 1–81 (2009).
   Google Scholar
• Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002–2007. J. Allergy Clin. Immunol.127, 145–152 (2011).
   PubMed Web of Science ®Google Scholar
• Chowdhury BA, Dal Pan G. The FDA and safe use of long-acting beta-agonists in the treatment of asthma. N. Engl. J. Med.362, 1169–1171 (2010).
   PubMed Web of Science ®Google Scholar
• Weinstein C, Staudinger H, Scott I et al. Dose counter performance of mometasone furoate/formoterol inhalers in subjects with asthma or COPD. Respir. Med.105, 979–988 (2011).
   PubMed Web of Science ®Google Scholar
• Dulera®, prescribing information. Merck and Co. Inc., Whitehouse Station, NJ, USA (2010).
   Google Scholar
• Symbicort®, prescribing information. AstraZeneca, Wilmington, DE, USA (2009).
   Google Scholar
• Advair Diskus®, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2011).
   Google Scholar
• Advair®, prescribing information. GlaxoSmithKline, Research Triangle Park, NC, USA (2011).
   Google Scholar
• Meltzer EO, Kuna P, Nolte H et al. Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function. Eur. Respr. J. doi:10.1183/09031936.00020310 (2011) (Epub ahead of print).
   Google Scholar
• Popper TL, Gentles MJ, Kung TT et al. Structure–activity relationships of a series of novel topical corticosteroids. J. Steroid Biochem.27, 837–843 (1987).
   PubMedGoogle Scholar
• Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm. Pharmacol. Ther.15, 35–50 (2002).
   PubMed Web of Science ®Google Scholar
• Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β 2-adrenoceptor agonist bronchodilator. Life Sci.52, 2145–2160 (1993).
   PubMed Web of Science ®Google Scholar
• Smith C, Kreutner W. In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung48, 956–960 (1998).
   PubMed Web of Science ®Google Scholar
• Stellato C, Atsuta J, Bickel CA, Schleimer RP. An in vitro comparison of commonly used topical glucocorticoid preparations. J. Allergy Clin. Immunol.104, 623–629 (1999).
   PubMed Web of Science ®Google Scholar
• Atsuta J, Plitt J, Bochner BS, Schleimer RP. Inhibition of VCAM-1 expression in human bronchial epithelial cells by glucocorticoids. Am. J. Respir. Cell Mol. Biol.20, 643–650 (1999).
   PubMed Web of Science ®Google Scholar
• Umland SP, Nahrebne DK, Razac S et al. The inhibitory effects of topically active glucocorticoids on IL-4, IL-5, and interferon-γ production by cultured primary CD4+ T cells. J. Allergy Clin. Immunol.100, 511–519 (1997).
   PubMed Web of Science ®Google Scholar
• Affrime MB, Cuss F, Padhi D et al. Bioavailability and metabolism of mometasone furoate following administration by metered-dose and dry-powder inhalers in healthy human volunteers. J. Clin. Pharmacol.40, 1227–1236 (2000).
   PubMed Web of Science ®Google Scholar
• Skoner DP, Gentile DA, Angelini B. Effect of therapeutic doses of mometasone furoate on cortisol levels in children with mild asthma. Allergy Asthma Proc.31, 10–19 (2010).
   PubMed Web of Science ®Google Scholar
• Shapiro GS, Yegen U, Xiang J et al. A randomized, double-blind, single-dose, crossover clinical trial of the onset and duration of protection from exercise-induced bronchoconstriction by formoterol and albuterol. Clin. Ther.24, 2077–2087 (2002).
   PubMed Web of Science ®Google Scholar
• Molimard M, Guenole E, Duvauchelle T et al. A randomized, double-blind, double-dummy, safety crossover trial comparing cumulative doses up to 96 microg of formoterol delivered via an HFA-134a-propelled pMDI vs. same cumulative doses of formoterol DPI and placebo in asthmatic patients. Respiration72(Suppl. 1), 28–34 (2005).
   PubMedGoogle Scholar
• Maspero JF, Nolte H, Cherrez-Ojeda I. Long-term safety of mometasone furoate/formoterol combination for treatment of patients with persistent asthma. J. Asthma47, 1106–1115 (2010).
   PubMed Web of Science ®Google Scholar
• Adcock IM, Maneechotesuwan K, Usmani O. Molecular interactions between glucocorticoids and long-acting beta2-agonists. J. Allergy Clin. Immunol.110, S261–S268 (2002).
   PubMedGoogle Scholar
• Chapman RW, Curran AK, House A et al. Effect of mometasone furoate (MF)/formoterol fumarate (F) combination (MF/F) on late-phase responses in allergen-challenged Brown Norway rats. Pulm. Pharmacol. Ther.24, 67–73 (2011).
   Google Scholar
• Nathan RA, Nolte H, Pearlman DS. Twenty-six-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg combination treatment in patients with persistent asthma previously receiving medium-dose inhaled corticosteroids. Allergy Asthma Proc.31, 269–279 (2010).
   PubMed Web of Science ®Google Scholar
• Weinstein SF, Corren J, Murphy K et al. Twelve-week efficacy and safety study of mometasone furoate/formoterol 200/10 microg and 400/10 microg combination treatments in patients with persistent asthma previously receiving high-dose inhaled corticosteroids. Allergy Asthma Proc.31, 280–289 (2010).
   PubMed Web of Science ®Google Scholar
• Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am. J. Respir. Crit. Care Med.180, 59–99 (2009).
   PubMed Web of Science ®Google Scholar
• Lloyd A, Price D, Brown R. The impact of asthma exacerbations on health-related quality of life in moderate to severe asthma patients in the UK. Prim. Care Respir. J.16, 22–27 (2007).
   PubMedGoogle Scholar
• Shingo S, Zhang J, Reiss TF. Correlation of airway obstruction and patient-reported endpoints in clinical studies. Eur. Respir. J.17, 220–224 (2001).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Wisniewski ME, Cox FM et al. Relationship between quality of life and clinical status in asthma: a factor analysis. Eur. Respir. J.23, 287–291 (2004).
   PubMed Web of Science ®Google Scholar
• Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol.113, 59–65 (2004).
   PubMed Web of Science ®Google Scholar
• Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control Questionnaire. Respir. Med.100, 616–621 (2006).
   PubMed Web of Science ®Google Scholar